Low- or no-opioid pain control is possible with EXPAREL
EXPAREL is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. When injected into the surgical site, EXPAREL turns off the body’s pain signals, numbing the area where surgery has occurred for several days following the procedure. To date, EXPAREL has been used in over 6 million patients.1
EXPAREL is the only non-opioid, single-dose, long-acting local analgesic approved for infiltration, field block, and interscalene brachial plexus nerve block.
EXPAREL infiltration provides significant long-lasting pain control while reducing opioid use*
EXPAREL vs bupivacaine HCI in total knee arthroplasty (TKA)2
With significantly better pain control through 48 hours (P < 0.04)
In a TKA study of EXPAREL vs bupivacaine HCI2
THROUGH DAY 2 & 3 POSTSURGERY
0%WITH BUPIVACAINE HCI(n=69)
Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, muscle spasms, vomiting.
EXPAREL vs placebo in a soft-tissue surgery3,4
With significantly better pain control through 72 hours (P = 0.0006†)
†Results vs placebo through 72 hours. Opioid reduction calculated based on geometric mean ratio.
In a hemorrhoidectomy study of EXPAREL vs placebo3
Through day 3 postsurgery
28% with exparel(n=95)
10% with placebo(n=94)
Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, dizziness, and muscle spasms.
Excellent results with EXPAREL as a single-dose interscalene brachial plexus nerve block
Significant postsurgical pain relief that lasts 48 hours with EXPAREL
VAS pain intensity scores with interscalene brachial plexus nerve block5
Primary endpoint was area under the curve (AUC) of the visual analog scale (VAS) pain intensity scores; 136 vs 254 (LSMD -118) for EXPAREL and placebo, respectively5PACU=postanesthesia care unit. LSMD=least squares mean difference. Results from a phase 3 double-blind, randomized, controlled trial that compared the postsurgical analgesia efficacy, safety, and pharmacokinetics of EXPAREL 133 mg (10 mL) and placebo in patients undergoing total shoulder arthroplasty or rotator cuff repair. Primary and secondary endpoints: pain intensity through 48 hours postsurgery, as measured by area under the curve (AUC) of visual analog scale (VAS) pain intensity scores and total postsurgical opioid consumption. Rescue opioids for pain were available upon patient request.
78% reduction in opioids through 48 hours
Postsurgical opioid consumption6
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the clinical trials